Tafenoquine (Arakoda™)

SELF ADMINISTRATION

Indications for Prior Authorization: 

  • Indicated for the prophylaxis of malaria in patients aged 18 years and older

Patients must meet the following criteria for the indication(s) above:

  • Patient is 18 years of age or older, AND
  • Patient is traveling to a malaria endemic area, AND
  • Patient has been tested for glucose-6-phosphate dehydrogenase (G6PD) deficiency and does not have G6PD deficiency prior to prescribing Arakoda™, AND
  • Patient will not breastfeed if the infant is found to be G6PD deficient or if G6PD status is unknown, AND
  • Patient does not have a history of psychotic disorders or current psychotic symptoms, AND
  • Patient has tried and failed or had clinically significant adverse effects to a preferred product (e.g. Atovaquone-Proguanil, Chloroquine, Doxycycline, Mefloquine, or Primaquine), unless contraindicated 

Dosing: 

  • Loading Regimen: 200mg (two 100mg tablets) once daily for 3 days
  • Maintenance Regimen: 200mg (two 100mg tablets) once weekly-start 7 days after the last loading regimen dose
  • Terminal Prophylaxis Regimen: 200mg (two 100mg tablets) one-time 7 days after the last maintenance dose

Approval: 

  • One time approval limited to duration of stay in malarious area

Last review date: December 9, 2019

WHA is closely monitoring the Coronavirus Disease 2019 (COVID-19). Learn more about COVID-19.